发明名称 Compounds
摘要 <p>Nitrogen substituted six membered compounds (I), and their tautomers, diastereomers, enantiomers, hydrates, mixtures, salts, or hydrates of the salts, preferably salts with inorganic or organic acids or bases, are new. Nitrogen substituted six membered compounds of formula (I) and their tautomers, diastereomers, enantiomers, hydrates, mixtures, salts, or hydrates of the salts, preferably salts with inorganic or organic acids or bases, are new. Either R 1>spiro[indane-2,3'-pyrrolidine]-2'-one group; and R 2>H or 1-3C-alkyl; or R 1>R 2>N : 2,8-diazaspiro[4.5]decane group or piperidine group; either R 3>e.g. H or 1-6C-alkylene-R 31>; and R 4>e.g. H or 1-6C-alkylene-R 41>; or R 3>R 4>N : e.g. saturated 5-7-membered heterocycle; U 1>, X : e.g. N or N-oxide; and V 1>, Y 1>e.g. N. With conditions. Full Definitions are given in the DEFINITIONS (Full Definitions) Field. An independent claim is included for the preparation of a medicament comprising mixing (I) with one or more inert carrier and/or diluent, in a non-chemical way. [Image] ACTIVITY : Analgesic; Antimigraine; Antidiabetic; Cardiovascular-Gen.; Antidiarrheic; Dermatological; Vulnerary; Antiinflammatory; Respiratory-Gen.; Gastrointestinal-Gen.; Antiarthritic; Antiallergic; Antiasthmatic; Vasotropic; Antibacterial; Immunosuppressive; Gynecological; Cytostatic; Endocrine-Gen.; Antilichen; Antipruritic; Osteopathic; Antirheumatic; Muscular-Gen.; Neuroprotective. MECHANISM OF ACTION : Calcitonin gene-related peptide antagonist. The ability of (I) to inhibit calcitonin gene-related peptide was tested using SK-N-MC cell. The results showed that 5-(6-(indolin-1-carbonyl)pyrimidin-4-ylamino)-1,3-dihydrospiro[inden-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one exhibited an inhibitory constant value of 15 nM.</p>
申请公布号 EP2062889(A1) 申请公布日期 2009.05.27
申请号 EP20070121350 申请日期 2007.11.22
申请人 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG 发明人
分类号 C07D403/14;A61K31/517;A61K31/527;A61K31/537;A61P3/10;A61P9/00;A61P17/00;A61P19/00;A61P25/06;C07D471/04;C07D471/10;C07D471/20;C07D498/10 主分类号 C07D403/14
代理机构 代理人
主权项
地址